EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy through the Lens of Non-Small Cell Lung Cancer

Robyn Stanley, Saoirse Flanagan, David O' Reilly, Ella Kearney, Jarushka Naidoo, Catríona M Dowling iD

Cancers · 30.05.2023 · 15 (11) · 2996

DOI: 10.3390/cancers15112996 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.05.2023. Verfasst von Robyn Stanley und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mid-Western Cancer foundation, All-Ireland Cancer Research Institute, Irish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, the discovery of CTLA-4 followed by PD-1 in the early 2000s led to the practice-changing clinical development of immune checkpoint inhibitors (ICI). Patients with lung cancer, including both small cell (SCLC) and non-small cell lung cancer (NSCLC), benefit from the most commonly used form of immunotherapy in immune checkpoint inhibitors (ICI), resulting in increased survival and quality of life. In NSCLC, the benefit of ICIs has now extended from advanced NSCLC to earlier stages of disease, resulting in durable benefits and the even the emergence of the word ‘cure’ in long term responders. However, not all patients respond to immunotherapy, and few patients achieve long-term survival. Patients may also develop immune-related toxicity, a small percentage of which is associated with significant mortality and morbidity. This review article highlights the various types of immunotherapeutic strategies, their modes of action, and the practice-changing clinical trials that have led to the widespread use of immunotherapy, with a focus on ICIs in NSCLC and the current challenges associated with advancing the field of immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

biomarkersclinical trialsimmune checkpoint inhibitorsimmune-related adverse eventsnon-small cell lung cancer

Autor:innen und Institutionen

  • School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.
  • Beaumont Hospital, D09 V2N0 Dublin, Ireland.
  • Department of Medicine, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland.
  • Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins University, Baltimore, MD 21218, USA.

ORCID-Profile: Catríona M Dowling

Förderung

  • Mid-Western Cancer foundation
  • All-Ireland Cancer Research Institute
  • Irish Cancer Society
  • Higher Education Authority
  • Department of Further and Higher Education, Research, Innovation and Science
  • Shared Island Fund
  • Irish Cancer Society Clinician Research Leader Award

Zitieren

APA

Stanley, R., Flanagan, S., Reilly, D. O., Kearney, E., Naidoo, J., & Dowling, C. M. (2023). Immunotherapy through the Lens of Non-Small Cell Lung Cancer. Cancers, 15(11), 2996. https://doi.org/10.3390/cancers15112996

Vancouver

Stanley R, Flanagan S, Reilly DO, Kearney E, Naidoo J, Dowling CM. Immunotherapy through the Lens of Non-Small Cell Lung Cancer. Cancers. 2023;15(11):2996. doi:10.3390/cancers15112996

BibTeX
@article{Stanley2023,
  author = {Stanley, Robyn and Flanagan, Saoirse and Reilly, David O' and Kearney, Ella and Naidoo, Jarushka and Dowling, Catríona M},
  title = {Immunotherapy through the Lens of Non-Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {2996},
  doi = {10.3390/cancers15112996}
}
Kostenlos starten →